Cingulate (CING) Stock Price

Cingulate Price

NYSE·CLOSED
4.36
​
Market closed

The consensus 12-month price target for Cingulate is 14.28 USD, about 227.5% above where the stock trades today. Of 10 analysts, 7 rate the stock a buy — an overall Buy consensus.

Cingulate stock price

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cingulate business model & stock analysis

Cingulate Inc is a US-based company operating in Pharmaceuticals industry. The company is headquartered in Kansas City, Kansas and currently employs 15 full-time employees. The company went IPO on 2021-10-07. Cingulate Inc. is a biopharmaceutical company. The firm is focused on the development, manufacturing, and commercialization of pharmaceutical products that utilize its precision timed release (PTR) drug delivery platform technology to create dosing schedules and drug release profiles that improve the lives of patients suffering from a multitude of commonly diagnosed conditions. The company focuses on the treatment of attention deficit/hyperactivity disorder (ADHD). The firm is in the development of two lead product candidates, such as CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine). Its CTx-1301 and CTx-1302 drug candidates both contain three releases of an active pharmaceutical ingredient combined into one small tablet dosage form. The Company’s CTx-1301 and CTx-1302 are being developed for the treatment of ADHD in the three core patient segments: children (ages 6-12), adolescents (ages 13-17), and adults (ages18+).

Frequently asked questions about Cingulate

Analysts currently set an average price target of 14.28 USD for the Cingulate stock (median: 14.28 USD), implying +227.5 % versus the latest price. The consensus is based on 10 analyst ratings.

10 analysts currently rate the Cingulate stock: 9 recommend buying, 1 holding and 0 selling. For 2026, analysts expect Cingulate to generate revenue of 2.90 M USD and earnings per share of -3.04 USD.

Converted at the current exchange rate, the Cingulate share trades at 3.89 EUR (4.36 USD).

The expected revenue of Cingulate is 2.90 M USD. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Cingulate is -16.48 M USD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Cingulate is currently -1.44. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Cingulate stock.

The price-to-sales ratio (P/S) of Cingulate is currently 8.17. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Cingulate stock.

The Eulerpool Quality Score for Cingulate is 2/10.

The ISIN of Cingulate is US17248W3034. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of Cingulate is CING. The ticker symbol is used to trade Cingulate shares on the stock exchange.

Fair ValueTerminal
4.27 USD
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Pharmaceuticals
Number of shares
Employees
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Currency
USD
Initial public offering
Oct 7, 2021
ISIN
US17248W3034
Cusip
17248W204
Market capitalization
33.70 M USDMicro Cap
52-Week Range
PEG
—
P/E ratio
P/Ee 2026
-1.44
P/Ee 2027
-1.75
P/Ee 2028
-2.62
P/Ee 2029
-7.47
P/Ee 2030
6.61
P/S
P/Se
8.17
EV/EBIT
—
P/B Ratio
13.43
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
-198.75 %
Last updated Oct 20, 2026, 1:31 PM

Cingulate Peer Group

All fundamentals and in-depth analysis of Cingulate

Our stock analysis for Cingulate stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Cingulate. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.